Medpace (MEDP) Expected to Announce Quarterly Earnings on Wednesday

Medpace (NASDAQ:MEDP) is projected to issue its Q2 2026 results after the market closes on Wednesday, July 22nd. Analysts expect Medpace to post earnings of $3.98 per share and revenue of $689.5340 million for the quarter. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 23, 2026 at 9:00 AM ET.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same quarter in the prior year, the business posted $3.67 earnings per share. Medpace’s revenue for the quarter was up 26.5% on a year-over-year basis. On average, analysts expect Medpace to post $17 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Medpace Stock Performance

Shares of MEDP opened at $537.73 on Monday. The firm has a market cap of $15.36 billion, a P/E ratio of 33.80, a PEG ratio of 2.69 and a beta of 1.15. Medpace has a 12 month low of $306.70 and a 12 month high of $628.92. The stock’s 50 day moving average is $478.10 and its two-hundred day moving average is $494.23.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 20.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. boosted its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Quarry LP acquired a new stake in shares of Medpace in the third quarter valued at about $35,000. Greenline Wealth Management LLC purchased a new position in shares of Medpace in the fourth quarter worth about $55,000. Group One Trading LLC lifted its stake in shares of Medpace by 120.0% in the fourth quarter. Group One Trading LLC now owns 100 shares of the company’s stock worth $56,000 after buying an additional 600 shares in the last quarter. Finally, Johnson Financial Group Inc. boosted its position in Medpace by 115.7% during the third quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock worth $57,000 after acquiring an additional 59 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Barclays decreased their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Robert W. Baird restated a “neutral” rating and set a $547.00 price objective (up from $477.00) on shares of Medpace in a research report on Wednesday, July 8th. Mizuho increased their price objective on shares of Medpace from $495.00 to $586.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Two research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Medpace currently has an average rating of “Hold” and an average target price of $469.50.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.